Edition:
United States

Mochida Pharmaceutical Co Ltd (4534.T)

4534.T on Tokyo Stock Exchange

8,530JPY
23 Mar 2017
Change (% chg)

¥-80 (-0.93%)
Prev Close
¥8,610
Open
¥8,500
Day's High
¥8,590
Day's Low
¥8,500
Volume
17,500
Avg. Vol
27,847
52-wk High
¥8,940
52-wk Low
¥7,010

Latest Key Developments (Source: Significant Developments)

Mochida Pharmaceutical signs contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd.
Monday, 6 Mar 2017 01:00am EST 

Mochida Pharmaceutical Co Ltd <4534.T>:Says it signed a contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd..  Full Article

Mochida Pharmaceutical to retire 465,000 treasury shares
Monday, 27 Feb 2017 12:05am EST 

Mochida Pharmaceutical Co Ltd <4534.T>: Says it will retire 465,000 shares (2.2 percent stake) of its common stock on March 23 .Says the total shares outstanding will be 20.5 million shares after the retirement.  Full Article

Albireo announces submission of new drug application for Elobixibat in Japan
Wednesday, 1 Feb 2017 08:00am EST 

Albireo Pharma Inc : Albireo announces submission of new drug application for Elobixibat in Japan .EA Pharma plans to co-market Elobixibat in Japan with Mochida Pharmaceutical Co., Ltd.  Full Article

Mochida Pharmaceutical gets manufacture and marketing approval for medicine of ulcerative colitis
Wednesday, 28 Sep 2016 02:00am EDT 

Mochida Pharmaceutical Co Ltd <4534.T>:Says it received manufacture and marketing approval for a medicine for the treatment of ulcerative colitis.  Full Article

Mochida Pharmaceutical raises consolidated full-year outlook for FY 2016
Monday, 25 Apr 2016 02:00am EDT 

Mochida Pharmaceutical Co Ltd:Says the company increased the consolidated full-year outlook for revenue to 92,200 mln yen from 90,000 mln yen for FY ended March 2016.Operating profit forecast increased to 12,100 mln yen from 10,000 mln yen.Ordinary profit forecast increased to 12,300 mln yen from 10,200 mln yen.Net profit forecast increased to 8,100 mln yen from 7,000 mln yen.Earnings per share increased to 407.91 yen from 352.51 yen.Comments increased income from medical products and decreased expenses on R& D are the main reasons for the forecast.  Full Article

Mochida Pharmaceutical announces agreement on joint development and joint sale of AJG533 in Japan
Thursday, 17 Mar 2016 09:00pm EDT 

Mochida Pharmaceutical Co Ltd:Says signed agreement on joint development and joint sale of AJG533 (Elobixibat) a treatment of chronic constipation in Japan, with AJINOMOTO PHARMACEUTICALS CO.,LTD.Says AJG533 ia under development by AJINOMOTO PHARMACEUTICALS CO.,LTD. in Japan.  Full Article

Mochida Pharmaceutical announces approval of MD-0901 in Japan
Friday, 30 Oct 2015 01:00am EDT 

Mochida Pharmaceutical Co Ltd:Obtained the marketing approval of therapeutic agent for ulcerative colitis (MD-0901) in Japan.  Full Article

Mochida Pharmaceutical raises consolidated mid-year outlook for FY 2016
Monday, 26 Oct 2015 02:30am EDT 

Mochida Pharmaceutical Co Ltd:Says the company increased the consolidated mid-year outlook for revenue to 45,300 mln yen from 44,000 mln yen, for the fiscal year ending March 31, 2016.Operating profit forecast increased to 7,000 mln yen from 5,700 mln yen.Ordinary profit forecast increased to 7,200 mln yen from 5,900 mln yen.Net profit forecast increased to 4,800 mln yen from 4,000 mln yen.Earnings per share increased to 241.71 yen from 201.43 yen.Comments steady growth in pharmaceuticals related business as the main reason for the forecast.  Full Article

Gene Techno Science forms business alliance with Mochida Pharmaceutical
Tuesday, 11 Aug 2015 02:30am EDT 

Gene Techno Science Co Ltd:Forms business alliance with Mochida Pharmaceutical, regarding development of follow-on biologics for cancer treatment.  Full Article

Mochida Pharmaceutical announces change of corporate auditor
Thursday, 14 May 2015 02:00am EDT 

Mochida Pharmaceutical Co Ltd:Appoints Ernst & Young ShinNihon LLC as corporate auditor to replace Deloitte Touche Tohmatsu LLC, on June 26.  Full Article

More From Around the Web

BRIEF-Mochida Pharmaceutical signs contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd.

* Says it signed a contract for joint development of sale of gout and hyperuricemia treatment FYU-981 in Japan with FUJIYAKUHIN Co., Ltd.